Arca
Skip to content
Tools
Tools

Transforming growth factor beta

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on TGFB1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2

Approved1

  • Luspatercept

Phase 31

  • Bintrafusp alfa

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      LuspaterceptApprovedBristol-Myers SquibbProtein or peptideInhibitorTransforming growth factor beta inhibitor42
      Bintrafusp alfaPhase 3Merck KGaAProtein or peptideBinding agentTransforming growth factor beta binding agent5

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
      Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and AnemiaLuspaterceptPhase 2Not yet recruitingPeking Union Medical College HospitalNov 16, 2026
      Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and ThrombocytopeniaLuspaterceptPhase 2Not yet recruitingCase Comprehensive Cancer CenterNov 13, 2026
      Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic SyndromesLuspaterceptPhase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaOct 26, 2026
      Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) PatientsLuspaterceptPhase 4Not yet recruitingUniversity Hospital, GrenobleSep 21, 2026
      First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic NeoplasmsLuspatercept—RecruitingBristol-Myers SquibbAug 7, 2026
      A Study of Luspatercept in People With AnemiaLuspaterceptPhase 2RecruitingMemorial Sloan Kettering Cancer CenterJul 24, 2026
      Luspatercept for CIA in AMLLuspaterceptPhase 1 / Phase 2RecruitingGuangdong Second Provincial General HospitalJun 23, 2026
      Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesLuspaterceptPhase 2 / Phase 3Not yet recruitingNanfang Hospital, Southern Medical UniversityJun 9, 2026
      Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaBintrafusp alfaPhase 2Active, not recruitingInstitut BergoniéMay 5, 2021
      Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaBintrafusp alfaPhase 1Active, not recruitingM.D. Anderson Cancer CenterJan 13, 2021
      TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapYBintrafusp alfaNot applicableRecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Jul 22, 2020
      Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaBintrafusp alfaPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 5, 2020
      Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesBintrafusp alfaPhase 1Active, not recruitingNational Cancer Institute (NCI)Jan 22, 2020

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3988637, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.